These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 32975758)

  • 21. Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.
    Prata J; Santos SG; Almeida MI; Coelho R; Barbosa MA
    J Neuroinflammation; 2017 Sep; 14(1):179. PubMed ID: 28870209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microglial activation in schizophrenia: Is translocator 18 kDa protein (TSPO) the right marker?
    Sneeboer MAM; van der Doef T; Litjens M; Psy NBB; Melief J; Hol EM; Kahn RS; de Witte LD
    Schizophr Res; 2020 Jan; 215():167-172. PubMed ID: 31699629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond.
    Meyer U; Schwarz MJ; Müller N
    Pharmacol Ther; 2011 Oct; 132(1):96-110. PubMed ID: 21704074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological treatment options for schizophrenia.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1606-13. PubMed ID: 22283758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.
    Bergman H; Rathbone J; Agarwal V; Soares-Weiser K
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD000459. PubMed ID: 29409162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation.
    Hu X; Zhou H; Zhang D; Yang S; Qian L; Wu HM; Chen PS; Wilson B; Gao HM; Lu RB; Hong JS
    J Neuroimmune Pharmacol; 2012 Mar; 7(1):187-201. PubMed ID: 21870076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammation in schizophrenia.
    Müller N; Myint AM; Schwarz MJ
    Adv Protein Chem Struct Biol; 2012; 88():49-68. PubMed ID: 22814706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging of translocator protein upregulation is selective for pro-inflammatory polarized astrocytes and microglia.
    Pannell M; Economopoulos V; Wilson TC; Kersemans V; Isenegger PG; Larkin JR; Smart S; Gilchrist S; Gouverneur V; Sibson NR
    Glia; 2020 Feb; 68(2):280-297. PubMed ID: 31479168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.
    Prestwood TR; Asgariroozbehani R; Wu S; Agarwal SM; Logan RW; Ballon JS; Hahn MK; Freyberg Z
    Behav Brain Res; 2021 Mar; 402():113101. PubMed ID: 33453341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
    Lieberman JA; Bymaster FP; Meltzer HY; Deutch AY; Duncan GE; Marx CE; Aprille JR; Dwyer DS; Li XM; Mahadik SP; Duman RS; Porter JH; Modica-Napolitano JS; Newton SS; Csernansky JG
    Pharmacol Rev; 2008 Sep; 60(3):358-403. PubMed ID: 18922967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia.
    Notter T; Coughlin JM; Gschwind T; Weber-Stadlbauer U; Wang Y; Kassiou M; Vernon AC; Benke D; Pomper MG; Sawa A; Meyer U
    Mol Psychiatry; 2018 Feb; 23(2):323-334. PubMed ID: 28093569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.
    Tardy M; Huhn M; Kissling W; Engel RR; Leucht S
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009268. PubMed ID: 25007358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia.
    MacDowell KS; Munarriz-Cuezva E; Caso JR; Madrigal JL; Zabala A; Meana JJ; García-Bueno B; Leza JC
    Neuropharmacology; 2017 Apr; 116():196-207. PubMed ID: 28039001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs.
    Svensson TH
    Brain Res Brain Res Rev; 2000 Mar; 31(2-3):320-9. PubMed ID: 10719159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring - the effect of antipsychotic drugs.
    Basta-Kaim A; Szczęsny E; Leśkiewicz M; Głombik K; Slusarczyk J; Budziszewska B; Regulska M; Kubera M; Nowak W; Wędzony K; Lasoń W
    Pharmacol Rep; 2012; 64(6):1400-10. PubMed ID: 23406750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia.
    Yoshida K; Takeuchi H
    Behav Brain Res; 2021 Mar; 402():113098. PubMed ID: 33417992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review.
    de Bartolomeis A; Barone A; Vellucci L; Mazza B; Austin MC; Iasevoli F; Ciccarelli M
    Mol Neurobiol; 2022 Oct; 59(10):6460-6501. PubMed ID: 35963926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical potential of minocycline for schizophrenia.
    Miyaoka T
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):376-81. PubMed ID: 18991666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.